Healthcare
Live Price
Offline$29.63
+4.29% today
1Y Change
+265.83%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sutro Biopharma, Inc. (STRO) is a Healthcare stock with a market cap of $300.00M and listed on NASDAQ. The stock last traded around $29.63 and up 265.8% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of +65.2%, EPS growth of +24.0%, a dividend yield of 0.0%. What stands out right now is revenue +65.2%, EPS +24.0%, free cash flow +8.1% with operating margin -150.2% and ROIC -144.5%. Valuation is more restrained than many high-expectation growth names at price/sales 3.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines STRO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STRO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
STRO Max Drawdown
-39.17%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for STRO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$61.9M
-8.7% YoY
FY Net Income
-$105.5M
+11.5% YoY
Free Cash Flow
-$97.0M
-2151.1% YoY
Revenue Growth
+65.2%
EPS Growth
+24.0%
Gross Margin
98.4%
Net Margin
-186.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 102M | 62M | 154M | 68M | 62M |
| Gross Profit | 95M | 55M | 147M | 59M | 52M |
| Operating Income | -105M | -238M | -89M | -129M | -99M |
| EBITDA | -98M | -180M | -68M | -105M | -98M |
| Net Income | -191M | -227M | -107M | -119M | -106M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 58M | 190M | 69M | 47M | 30M |
| Total Assets | 174M | 387M | 471M | 407M | 341M |
| Total Liabilities | 306M | 343M | 321M | 190M | 89M |
| Shareholder Equity | -132M | 45M | 150M | 217M | 253M |
| Total Debt | 16M | 23M | 34M | 55M | 57M |
| Net Debt | -42M | -167M | -36M | 8M | 27M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
82M
-2401.5% YoY
Capital Expenditures
15M
-95.0% YoY
Free Cash Flow
97M
-2151.1% YoY
Key ratios
Gross Margin
98.4%
Operating Margin
-150.2%
Net Margin
-186.5%
ROE
275.3%
Debt / Equity
-1.78x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.